Rola białka C-reaktywnego w ocenie ryzyka chorób układu sercowo-naczyniowego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2011
Słowa kluczowe:
stratyfikacja ryzyka, białko C-reaktywne, statyny
##plugins.themes.bootstrap3.article.main##
Abstrakt
Stratyfikacja ryzyka odgrywa istotną rolę w codziennej praktyce klinicznej. Najważniejszym elementem jest ocena tzw. klasycznych czynników ryzyka chorób układu sercowo-naczyniowego (CVD). Innym ważnym elementem oceny ryzyka u pacjenta może być użycie gotowych skal opartych na czynnikach ryzyka chorób układu krążenia, np. skali Framingham lub SCORE (Systematic Coronary Risk Evaluation). Ocena stężeń markerów biochemicznych może być także pomocna w stratyfikacji ryzyka CVD. Białko C-reaktywne (CRP) jest dobrze udokumentowanym markerem reakcji zapalnej, jednak wyniki badań odnośnie roli CRP w ocenie ryzyka CVD są niejednoznaczne.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Hrynkiewicz-Szymańska, A., & Szymański , F. M. (2011). Rola białka C-reaktywnego w ocenie ryzyka chorób układu sercowo-naczyniowego . Medycyna Faktów , 4(1(10), 37-42. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2548
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Yusuf S., Hawken S., Ounpuu S. et al.: INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
2. O’Donnell M.J., Xavier D., Liu L. et al.: Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376: 112-123.
3. Pepys M.B., Hirschfield G.M.: C-reactive protein: a critical update. J. Clin. Invest. 2003; 111: 1805-1812.
4. Wald D.S., Kasturiratne A., Bestwick J.P.: The value of C-reactive protein in screening for future coronary heart disease events. J. Med. Screen. 2009; 16: 212-214.
5. de Beer F.C., Soutar A.K., Baltz M.L. et al.: Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J. Exp. Med. 1982; 156: 230-242.
6. Zhang Y.X., Cliff W.J., Schoefl G.I. et al.: Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375-379.
7. Danesh J., Whincup P., Walker M. et al.: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
8. Danesh J., Wheeler J.G., Hirschfield G.M. et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004; 350: 1387-1397.
9. Ridker P.M., Danielson E., Fonseca F.A. et al.: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N. Engl. J. Med. 2008; 359: 2195-2207.
10. Ridker P.M., Danielson E., Fonseca F.A. et al.: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
11. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur. J. Cardiovasc. Prev. Rehabil. 2003; 10: S1-S78.
12. Ridker P.M., Cannon C.P., Morrow D. et al.: C-Reactive Protein Levels and Outcomes after Statin Therapy. N. Engl. J. Med. 2005; 352: 20-28.
13. Kaptoge S., Di Angelantonio E., Lowe G. et al.: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-140.
14. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J. Am. Coll. Cardiol. 2010; 56: 2182-2199.
15. Emberson J., Bennett D., Link E. et al.: Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study. Lancet 2011; 377: 469-476.
2. O’Donnell M.J., Xavier D., Liu L. et al.: Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376: 112-123.
3. Pepys M.B., Hirschfield G.M.: C-reactive protein: a critical update. J. Clin. Invest. 2003; 111: 1805-1812.
4. Wald D.S., Kasturiratne A., Bestwick J.P.: The value of C-reactive protein in screening for future coronary heart disease events. J. Med. Screen. 2009; 16: 212-214.
5. de Beer F.C., Soutar A.K., Baltz M.L. et al.: Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J. Exp. Med. 1982; 156: 230-242.
6. Zhang Y.X., Cliff W.J., Schoefl G.I. et al.: Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375-379.
7. Danesh J., Whincup P., Walker M. et al.: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
8. Danesh J., Wheeler J.G., Hirschfield G.M. et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004; 350: 1387-1397.
9. Ridker P.M., Danielson E., Fonseca F.A. et al.: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N. Engl. J. Med. 2008; 359: 2195-2207.
10. Ridker P.M., Danielson E., Fonseca F.A. et al.: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
11. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur. J. Cardiovasc. Prev. Rehabil. 2003; 10: S1-S78.
12. Ridker P.M., Cannon C.P., Morrow D. et al.: C-Reactive Protein Levels and Outcomes after Statin Therapy. N. Engl. J. Med. 2005; 352: 20-28.
13. Kaptoge S., Di Angelantonio E., Lowe G. et al.: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-140.
14. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J. Am. Coll. Cardiol. 2010; 56: 2182-2199.
15. Emberson J., Bennett D., Link E. et al.: Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study. Lancet 2011; 377: 469-476.